National Pension Service Cuts Position in IDEXX Laboratories, Inc. $IDXX

National Pension Service reduced its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 9.5% during the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 114,378 shares of the company’s stock after selling 12,022 shares during the period. National Pension Service owned approximately 0.14% of IDEXX Laboratories worth $61,345,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Opal Wealth Advisors LLC acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at approximately $29,000. Migdal Insurance & Financial Holdings Ltd. increased its position in shares of IDEXX Laboratories by 55.6% in the first quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company’s stock valued at $35,000 after buying an additional 30 shares in the last quarter. Ameritas Advisory Services LLC acquired a new position in shares of IDEXX Laboratories during the 2nd quarter worth $36,000. WPG Advisers LLC purchased a new stake in shares of IDEXX Laboratories in the 1st quarter worth about $37,000. Finally, Bank of Jackson Hole Trust grew its stake in IDEXX Laboratories by 328.6% in the 1st quarter. Bank of Jackson Hole Trust now owns 90 shares of the company’s stock valued at $39,000 after acquiring an additional 69 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Stock Performance

Shares of NASDAQ:IDXX opened at $701.48 on Friday. The business has a 50-day moving average of $650.81 and a two-hundred day moving average of $585.94. The firm has a market capitalization of $56.01 billion, a PE ratio of 58.41, a P/E/G ratio of 4.06 and a beta of 1.62. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.11 and a quick ratio of 0.79. IDEXX Laboratories, Inc. has a 12 month low of $356.14 and a 12 month high of $735.00.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.14 by $0.08. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The company had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.07 billion. During the same period in the previous year, the firm earned $2.80 earnings per share. IDEXX Laboratories’s revenue for the quarter was up 13.3% on a year-over-year basis. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, research analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director M Anne Szostak sold 2,187 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total value of $1,415,710.71. Following the completion of the sale, the director directly owned 262 shares in the company, valued at approximately $169,600.46. This represents a 89.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Nimrata Hunt sold 9,425 shares of the business’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $703.34, for a total value of $6,628,979.50. Following the transaction, the executive vice president owned 21,149 shares in the company, valued at approximately $14,874,937.66. This represents a 30.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.98% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

IDXX has been the subject of several recent research reports. Morgan Stanley raised their price target on IDEXX Laboratories from $765.00 to $805.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 4th. Weiss Ratings reiterated a “buy (b-)” rating on shares of IDEXX Laboratories in a research note on Wednesday, October 8th. Wall Street Zen upgraded IDEXX Laboratories from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. UBS Group lifted their price target on IDEXX Laboratories from $710.00 to $750.00 and gave the company a “neutral” rating in a report on Tuesday, November 4th. Finally, Leerink Partners set a $785.00 price objective on shares of IDEXX Laboratories in a report on Monday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $730.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.